KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $847.0 million.

  • Acadia Pharmaceuticals' Cash & Current Investments rose 4982.74% to $847.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $847.0 million, marking a year-over-year increase of 4982.74%. This contributed to the annual value of $756.0 million for FY2024, which is 7226.09% up from last year.
  • Acadia Pharmaceuticals' Cash & Current Investments amounted to $847.0 million in Q3 2025, which was up 4982.74% from $762.0 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Cash & Current Investments peaked at $847.0 million during Q3 2025, and registered a low of $345.9 million during Q3 2023.
  • Moreover, its 5-year median value for Cash & Current Investments was $500.9 million (2024), whereas its average is $530.4 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first crashed by 2281.04% in 2022, then soared by 7226.09% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Cash & Current Investments (Quarter) stood at $520.7 million in 2021, then decreased by 19.95% to $416.8 million in 2022, then grew by 5.29% to $438.9 million in 2023, then soared by 72.26% to $756.0 million in 2024, then rose by 12.04% to $847.0 million in 2025.
  • Its last three reported values are $847.0 million in Q3 2025, $762.0 million for Q2 2025, and $681.6 million during Q1 2025.